| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7632778 | Journal of Pharmaceutical and Biomedical Analysis | 2012 | 7 Pages |
Abstract
⺠sVEGFR-3 is a potential biomarker for the anti-angiogenic activity of tyrosine kinase inhibitors. ⺠An ELISA for the quantification of sVEGFR-3 in human plasma was successfully validated. ⺠The assay performance was confirmed in two clinical trials including healthy volunteers and cancer patients. ⺠The decrease of sVEGFR-3 levels after sunitinib intake was well described and occurs also in the absence of any tumor. ⺠With the assay validation and the characterization of sVEGFR-3 behavior in human plasma the first step in the biomarker validation process for sVEGFR-3 was achieved.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Friederike Kanefendt, Andreas Lindauer, Klaus Mross, Uwe Fuhr, Ulrich Jaehde,